Table 3.
Population Attributable Risks Associated with Physical Inactivity in Different Geographical Regions
| Outcome | Central Asia, Middle East, & North Africa | Central & Eastern Europe | East & Southeast Asia | High-Income Asia Pacific | High-Income Western Countries | Latin America & Caribbean | Oceania | South | Sub-Saharan Africa |
|---|---|---|---|---|---|---|---|---|---|
| Prevalence (95% CI)*,ǂ | 32.8 (31.0 to 32.2) | 23.4 (20.9 to 28.0) | 17.3 (15.8 to 22.1) | 35.7 (34.4 to 37.0) | 36.8 (34.6 to 38.4) | 39.1 (37.8 to 40.6) | 16.3 (14.3 to 20.7) | 33.0 (23.0 to 51.7) | 21.4(19.1 to 23.3) |
| PARsemi (95% CI) | |||||||||
| All-Cause Mortality | 8.4 (6.5 to 10.4) | 6.2 (4.6 to 7.8) | 4.6 (3.4 to 6.0) | 9.1 (7.0 to 11.2) | 9.3 (7.2 to 11.5) | 9.9 (7.7 to 12.2) | 4.4 (3.2 to 5.6) | 8.5 (5.0 to 12.3) | 5.7 (4.3 to 7.1) |
| CVD Mortality | 9.0 (7.4 to 10.6) | 6.6 (5.2 to 8.0) | 4.9 (3.9 to 6.1) | 9.7 (8.1 to 11.4) | 9.9 (8.3 to 11.7) | 10.5 (8.7 to 12.4) | 4.7 (3.6 to 5.8) | 9.0 (5.5 to 12.8) | 6.0 (3.9 to 7.2) |
| Coronary Heart Disease | 5.9 (4.2 to 7.6) | 4.3 (3.0 to 5.7) | 3.2 (2.2 to 4.3) | 6.4 (4.6 to 8.2) | 6.5 (4.7 to 8.4) | 6.9 (5.0 to 8.9) | 3.0 (2.1 to 4.1) | 5.9 (3.3 to 9.0) | 3.9 (2.8 to 5.2) |
| Stroke | 5.9 (3.5 to 8.5) | 4.3 (2.5 to 6.2) | 3.2 (1.8 to 4.7) | 6.4 (3.8 to 9.2) | 6.5 (3.9 to 9.4) | 6.9 (4.1 to 10.0) | 3.0 (1.7 to 4.4) | 5.9 (2.9 to 9.6) | 3.9 (2.2 to 5.7) |
| Hypertension | 1.9 (1.1 to 2.8) | 1.4 (0.8 to 2.0) | 1.0 (0.6 to 1.5) | 2.1 (1.2 to 3.0) | 2.2 (1.3 to 3.1) | 2.3 (1.3 to 3.3) | 1.0 (0.6 to 1.4) | 1.9 (1.0 to 3.2) | 1.3 (0.7 to 1.8) |
| Type 2 Diabetes | 5.3 (3.8 to 6.9) | 3.8 (2.7 to 5.1) | 2.9 (2.0 to 3.9) | 5.7 (4.0 to 7.5) | 5.9 (4.2 to 7.7) | 6.2 (4.5 to 8.1) | 2.7 (1.8 to 3.7) | 5.3 (3.0 to 8.0) | 3.5 (2.5 to 4.6) |
| Bladder Cancer | 2.6 (−1.4 to 7.1) | 1.8 (−1.0 to 5.2) | 1.4 (−0.8 to 3.8) | 2.8 (−1.5 to 7.7) | 2.9 (−1.7 to 7.9) | 3.0 (−1.7 to 8.5) | 1.3 (−0.7 to 3.6) | 2.6 (−1.5 to 7.5) | 1.7 (−0.9 to 4.7) |
| Breast Cancer* | 3.5 (1.6 to 5.4) | 2.2 (0.9 to 3.5) | 1.5 (0.6 to 2.5) | 3.3 (1.5 to 5.3) | 3.7 (1.6 to 5.8) | 3.8 (1.8 to 6.0) | 1.8 (0.8 to 2.9) | 3.7 (1.4 to 6.7) | 2.2 (1.0 to 3.5) |
| Colon Cancer | 3.5 (1.4 to 5.7) | 2.5 (1.0 to 4.2) | 1.9 (0.7 to 3.2) | 3.8 (1.6 to 6.1) | 3.9 (1.6 to 6.4) | 4.1 (1.7 to 6.7) | 1.8 (0.7 to 2.9) | 3.5 (1.3 to 6.3) | 2.3 (0.9 to 3.7) |
| Endometrial Cancer* | 3.5 (−0.6 to 8.0) | 2.2 (−0.3 to 5.1) | 1.5 (−0.3 to 3.5) | 3.3 (−0.5 to 7.6) | 3.7 (−0.6 to 8.3) | 3.8 (−0.6 to 8.7) | 1.8 (−0.3 to 4.2) | 3.7 (−0.6 to 9.3) | 2.2 (−0.4 to 5.0) |
| Esophageal Cancer | 8.4 (−3.0 to 24.4) | 6.2 (−2.1 to 17.9) | 4.6 (−1.7 to 13.7) | 9.1 (−3.2 to 26.6) | 9.3 (−3.3 to 27.7) | 9.9 (−3.5 to 29.2) | 4.4 (−1.6 to 12.9) | 8.5 (−2.9 to 25.9) | 5.7 (−2.0 to 16.6) |
| Gastric Cancer | 8.1 (−0.3 to 19.0) | 5.9 (−0.2 to 14.2) | 4.5 (−0.2 to 10.6) | 8.8 (−0.6 to 20.5) | 9.0 (−0.4 to 21.6) | 9.6 (−0.5 to 22.3) | 4.2 (−0.2 to 10.1) | 8.2 (−0.3 to 20.3) | 5.5 (−0.2 to 12.8) |
| Renal Cancer | 8.4 (2.8 to 14.9) | 6.2 (2.1 to 11.1) | 4.6 (1.6 to 8.3) | 9.1 (3.0 to 16.3) | 9.3 (3.1 to 16.8) | 9.9 (3.4 to 17.4) | 4.4 (1.4 to 7.9) | 8.5 (2.5 to 16.2) | 5.7 (1.8 to 10.2) |
| Dementia | 9.5 (2.8 to 17.5) | 7.0 (2.2 to 12.9) | 5.3 (1.6 to 9.7) | 10.3 (3.2 to 18.8) | 10.5 (3.3 to 19.1) | 11.1 (3.6 to 20.4) | 5.0 (1.5 to 9.3) | 9.6 (2.6 to 19.1) | 6.4 (2.0 to 11.8) |
| Depression | 8.4 (1.5 to 16.9) | 6.2 (1.0 to 12.4) | 4.6 (0.8 to 9.4) | 9.1 (1.6 to 18.4) | 9.3 (1.5 to 18.7) | 9.9 (1.7 to 20.0) | 4.4 (0.8 to 9.0) | 8.5 (1.3 to 18.1) | 5.7 (1.0 to 11.4) |
*
The prevalence of insufficient physical activity among women (Central Asia, Middle East & North Africa: 39.9 %; 95% CI: 37.9 to 42.7; Central & Eastern Europe: 24.7%; 95% CI: 21.7 to 33.9; East & Southeast Asia: 16.9%; 95% CI: 14.9 to 25.7; High-Income Asia Pacific: 38.3%; 95% CI: 37.4 to 42.6; High-Income Western: 42.3%; 95% CI: 39.1 to 45.4; Latin America & Caribbean: 43.7%; 95% CI: 42.9 to 46.5; Oceania: 203.%; 95% CI: 18.8 to 28.7; South Asia: 43.0%; 95% CI: 29.6 to 74.9; Sub-Saharan Africa: 24.8%; 95% CI: 21.8 to 27.2) was applied to compute the PARsemi for breast cancer and endometrial cancer.
ǂ
Prevalence estimates were obtained from Guthold et al.4